Statement regarding recent speculation

The Board of Swedish Orphan Biovitrum AB (publ) notes the recent speculation in the press and elsewhere regarding a potential acquisition of the company.

The Board confirms that it has received a preliminary and conditional non-binding proposal in relation to a possible offer for all shares issued by the company.

There can be no certainty that an offer will be made, nor as to the terms of any such offer. A further announcement will be made when appropriate.


About Sobi

Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of specialty and rare disease products for partner companies across Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2014, Sobi had total revenues of SEK 2.6 billion (USD 380 M) and about 600 employees. The share (STO: SOBI) is listed on NASDAQ Stockholm. More information is available at

For more information please contact
Media relations                                   Investor relations
Oskar Bosson                                     Jörgen Winroth
Head of Communications                 VP, Head of Investor Relations
T: +46 70 410 71 80                          T: +1 347-224-0819, +1 212-579-0506,
                                                              +46 8 697 2135
[email protected]              [email protected]

Sobi announces the information set out in this press release pursuant to the Swedish Securities Market Act. The information was submitted for publication at 08:05 CET on 27 April 2015.

Suggested Articles

Q32 Bio raised $60 million to push its lead antibody through the clinic and bolster its pipeline and the technology behind it.

Sanofi is teaming up with Merck while AstraZeneca taps Arcus as the future of cancer work is very much made together.

The action follows the FDA’s decision to reject a filing for approval of the JAK1 inhibitor in rheumatoid arthritis due to toxicity concerns.